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Abstract
Background: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab (ALI)
and evolocumab (EVO) have previously been evaluated through controlled clinical trials with selective patient groups.
Post-commercially, in patients with heterozygous familial hypercholesterolemia (HeFH) and/or cardiovascular disease
(CVD) with suboptimal LDL cholesterol (LDLC) lowering on maximal tolerated cholesterol lowering therapy, we assessed
efficacy and safety of ALI and EVO.
Methods: Post-commercially, we started 25 patients on ALI 75 mg, 15 on ALI 150 mg, and 32 on EVO 140 mg bi-weekly
added to entry LDLC lowering regimen, with follow-up for a median 24 weeks. History, physical exam, demographics, and
adverse event data were collected. Changes in LDLC and AHA and NIH calculated 10-year CVD risks were assessed on ALI
and EVO.
Results: Of 72 patients, 25 had HeFH only, 25 CVD only, 22 had both, median age was 65 years, 63% females, 38% males,
86% Caucasian, 11% African-Americans, 17% diabetics, 63% on anti-hypertensives, and 7% smokers. At entry, 30 (42%)
were on a statin and 42 (58%) could not tolerate any statins.
At 24-weeks, median LDLC decreased on ALI 75 mg from 117 to 62 mg/dL (−54%), on ALI 150 mg from 175 to 57 mg/dL
(−63%), and on EVO 140 mg from 165 to 69 mg/dL (−63%), p <0.0001 for all. Absolute and percent LDLC
reduction did not differ (p >.05) between ALI 150 and EVO 140 mg, but were less on ALI 75 mg vs ALI 150 mg
and EVO 140 mg (p <.05).
Percent reductions in 10-year CVD risks by AHA and NIH calculators, respectively were ALI 75 mg −22 and −44%,
ALI 150 mg −31 and −50%, and EVO 140 mg −29 and −56%, p ≤.002 for all.
The three most common adverse events included flu-like myositis 10%, respiratory tract symptoms 8%, and injection
site reaction 6%.
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Conclusion: In patients with HeFH and/or CVD, LDLC was lowered by 63% on EVO and ALI 150 mg, and 54% on ALI
75 mg. Adverse events were minimal and tolerable. ALI and EVO represent paradigm shifts in LDLC lowering. Long term,
post-commercial safety and efficacy remain to be determined.
Keywords: PCSK9 Inhibitor, Efficacy, Safety, Cardiovascular risk, Alirocumab, Evolocumab, Hypercholesterolemia, Low-
density lipoprotein
Background
With coronary artery disease and stroke being the num-
ber one cause of mortality in the United States [1], there
is undeniable evidence that high LDL cholesterol
(LDLC) contributes to an increased risk of cardiovascu-
lar disease (CVD). According to the CDC, approximately
78 million Americans (>21 years age) are eligible for
cholesterol lowering medication, but only 55% are taking
such therapy, of whom about 90% are on a statin [2].
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors such as alirocumab (ALI) and evolocumab
(EVO) have transformed LDLC lowering [3]. PCKS9 in-
hibitors are indicated in patients with heterozygous fa-
milial hypercholesterolemia (HeFH), Simon Broom’s
Criteria [4] and/or WHO Dutch Lipid Criteria [5], and/
or in patients with cardiovascular disease (CVD) whose
LDLC lowering is suboptimal despite maximal tolerated
cholesterol lowering therapy.
Previously, we have projected that an estimated 24 mil-
lion Americans could be eligible for PCSK9 inhibitor ther-
apy [6, 7]. Prior to commercialization, efficacy and safety
of ALI and EVO in patients has been evaluated through
randomized controlled clinical trials [8–12], which have
stringent inclusion and exclusion criteria, creating a highly
selective cohorts of study patients.
ALI ODYSSEY Phase III studies demonstrated that the
mean percentage change in calculated low-density lipopro-
tein cholesterol (LDLC) from baseline to week 24 beyond
statin effect was −61% versus 0.8% (placebo), p <0.001
[9, 13]. In 2,461 patients treated with ALI 150 mg, 796
(32%) had two consecutive LDLC levels <25 mg/dl while
288 (12%) had two consecutive LDLC levels <15 mg/dl
[10]. In ODDYSSEY COMBO I, in addition to concurrent
LDLC lowering therapy, ALI 75 mg produced a 45.6%
LDLC decrease from baseline at 24 weeks [3]. Further-
more, in the OSLER-1 and OSLER-2 phase III trials, EVO
140 mg reduced LDLC by −61% at the median 12-week
treatment mark, beyond statin effect. In a pool of 2,651
patients receiving EVO 140 mg, 1609 (61%) had at least
one LDLC <25 mg/dl [11].
Compared to placebo in double-blind studies, there
were minimal adverse reactions to the PCSK9 inhibitors
with the difference being consistently <2% [9, 11].
Preliminary results of safety-efficacy controlled clinical
trials, although not powered or designed to definitively
assess CVD events, have revealed approximately 50%
CVD risk reduction [9, 11].
Statin intolerance, predominantly characterized by my-
algia, myositis, and myopathy, occurs in 10-29% of
statin-treated patients [14, 15]. PCSK9 inhibitor therapy
could substantially benefit these patients [6]. In the
GAUSS-3 study of patients with previous statin intoler-
ance, 43% of patients on atorvastatin had muscular
symptoms. When these patients were enrolled in Phase
B, which compared ezetimibe and placebo versus EVO
and placebo, 29% experienced myalgias on ezetimibe
versus 21% of those on EVO [8]. Furthermore, LDLC re-
duction from baseline on ezetimibe was −17% versus
−53% on EVO at 24 weeks. In patients with statin in-
tolerance, EVO was effective and well-tolerated [8].
Before 2013 [16], an LDLC target of <70 mg/dl was con-
sidered to be optimal for patients at high risk of coronary
heart disease, and/or for type II diabetics. In treated pa-
tients from NHANES data, only 28% achieved LDLC <
70 mg/dl [17]. In 2014, the ACC/AHA guidelines [18]
were no longer focused on LDLC targets <70 mg/dl, but
suggested that high dose statins be given to patients
matched to their calculated 10-year CVD event risk. It
was suggested that LDLC be reduced by at least 50% in
high risk patients, and by 30–49% in primary prevention
of high risk patients [18]. In 2016, ACC Expert Consensus
Decision Pathway re-introduced treatment thresholds, in-
cluding LDLC <70 mg/dl in high risk patients with CVD
[19]. For patients with clinically stable atherosclerotic car-
diovascular disease (ASCVD), LDLC was targeted to
<100 mg/dl and for those with CVD and comorbidities,
LDLC targeted to <70 mg/dl [19].
Our specific aim, in a post-commercialization, open label,
real world environment, was to assess the safety and effi-
cacy of ALI and EVO in lowering LDLC, and subsequent
change in calculated 10-year CVD risk in patients with
HeFH and/or CVD referred to a regional cholesterol center
for diagnosis and treatment of hypercholesterolemia.
Methods
The procedures were in accordance with the ethical stan-
dards of human experimentation, and approved by The
Jewish Hospital Institutional Review Board (JH#12-03,
15–06). Informed consent was provided and signed prior
to initiation of the study.
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Since the commercialization of PCSK9 inhibitors in July
2015, at our regional cholesterol center, 72 patients were
started on either EVO or ALI based on qualifications for
HeFH (HeFH, Simon Broom’s Criteria [4], WHO Dutch
Lipid Criteria score >8 [5]) and/or CVD with suboptimal
LDLC lowering despite maximal tolerated cholesterol low-
ering therapy, including statin doses down to zero. HeFH
was assessed by the presence of tendon xanthomas and
LDLC ≥190 mg/dl and/or personal or family history of
premature cardiovascular disease and/or history of severe
hypercholesterolemia. CVD was defined as carotid artery
disease, history of stroke/TIA, coronary artery disease,
congestive heart failure associated with CVD, and periph-
eral vascular disease.
Prior to initiation of therapy, all patients were counseled
on a low cholesterol and saturated fat diet, and received
follow-up counseling at serial visits. Instructions on how
to use PCSK9 inhibitor auto-injector pens, education on
its mechanism of action, side effects, and actions to be
taken for missed doses were provided. Emergency contact
information was given.
ALI and EVO were given in addition to patients’ entry
maximal tolerated cholesterol lowering regimens. Insur-
ance formulary coverage was taken into consideration
when deciding whether to use ALI or EVO. If entry
LDLC was ≤130 mg/dl, ALI 75 mg/ml was used, while
for LDLC >130 mg/dl, ALI 150 mg was used, while EVO
140 mg was used for any entry LDLC. Sub-cutaneous
auto-injector pens were used every two weeks.
All patients were followed for a median of 24 weeks,
25th-75th percentile 24–28 weeks. We obtained a de-
tailed history (especially cardiovascular history, docu-
mented HeFH and history of statin intolerance), physical
examination, and lab draws at baseline and after starting
therapy at 4, 12, and 24 weeks. Patient characteristics
obtained included: age, gender, weight, body mass index,
systolic and diastolic blood pressures, history of diabetes,
smoking, and treatment with anti-hypertensive medica-
tions. Adverse events after the initiation of the therapy
were recorded and appropriate changes were made as
needed. The changes in 10-year cardiovascular risk were
assessed using ACC/AHA [18] and NIH Framingham
[20] risk calculators.
Statistical software SAS version 9.4 and Prism were
used for data analysis and presentation. Paired Wilcoxon
analysis was used to compare entry and follow-up data.
General linear models were used to assess differences in
LDLC lowering for the two ALI doses and EVO after
adjusting for treatment duration, age, race, gender, BMI,
presence or absence of statin intolerance, HeFH (+/−),
and CVD (+/−). General linear models were also used to
compare absolute and percent changes in LDLC in pa-
tients with and without entry statin intolerance, after
adjusting for PCSK9 treatment type, treatment duration,
age, race, gender, BMI, HeFH (+/−), CVD (+/−), and
entry LDLC.
Absolute changes in LDLC were also assessed in a
mixed effect model for repeated measures.
Results
Table 1 displays entry characteristics of our cohort of 72
patients. Median age at entry was 65 years, 86% Cauca-
sian, 11% African-American, 1% Asian, 1% Indian. Of
the 72 patients, 63% were female, 38% male, 17% had
diabetes, 7% smoked, and 63% were on anti-hypertensive
medication. Of the 72 patients, 25 (35%) had HeFH only,
25 (35%) had CVD only, and 22 (31%) had both HeFH
and CVD (Table 1). Of the 72 patients, 42 (58%) could
not tolerate any dose of statin (Table 1). Before starting
PCSK9 inhibitor therapy, 16 patients were taking a statin
only, 5 statin and ezetimibe, 2 statin and colesevelam, 7
statin, ezetimibe, and colesevelam, and 11 ezetimibe
and/or colesevelam (Table 1).
Tables 2, 3, and 4 display 25th, 50th, and 75th percen-
tiles for LDLC and total cholesterol, triglyceride, and
HDL cholesterol categorized by drug group and further
characterized by HeFH and CVD, Table 3. On ALI
75 mg, entry LDLC fell from a median of 117–62 mg/dl,
a 54% decrement, Table 2. On ALI 150 mg, entry LDLC
fell from a median of 175–57 mg/dl, a 63% reduction,
and on EVO 140 mg, entry LDLC fell from 165 to
69 mg/dl, a 63% reduction, Table 2, Fig. 1. Median, 25th
and 75th percentiles for follow-up were 24, 24, and
28 weeks, Table 1.
Figures 1, 2, 3 display 25th, 50th, and 75th percentiles of
LDLC levels at study entry and 4, 12, and 24 weeks follow-
up in the ALI 75 mg, ALI 150 mg, and EVO 140 mg
groups. Median LDLC in the ALI 75 mg group decreased
from 117 to 68 mg/dl at 4 weeks, 61 mg/dl at 12 weeks,
and 62 mg/dl at 24 weeks (p <.0001 for all). Median LDLC
in the ALI 150 mg group decreased from 175 to 66 mg/dl
at 4 weeks, 68 mg/dl at 12 weeks and 57 mg/dl at 24 weeks
(p <.0001 overall, Fig. 2). Median LDLC in the EVO
140 mg group decreased from 165 to 83 mg/dl at 4 weeks,
75 mg/dl at 12 weeks, and 69 mg/dl at 24 weeks (p <.0001
for all, Fig. 3). For each drug group, there was a sharp re-
duction in LDLC by 4 weeks, which remained stable at 12
and 24 weeks (Figs. 1, 2, 3).
In the mixed effect model for repeated measures,
LDLC reductions on ALI 75, ALI 150, and EVO 140 mg
were significant, p<. 0001 for all.
Table 3 demonstrates the number of patients who had
attained at least one measurement of LDLC <70 mg/dl
while on ALI 75 mg, ALI 150 mg, or EVO 140 mg. For
the total cohort, median entry LDLC was 149 mg/dl,
177 mg/dl for HeFH only, 131 mg/dl for CVD only, and
169 mg/dl for both HeFH and CVD, Table 3. Of the 25
patients in the HeFH only group, 12 (48%) achieved
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Table 1 72 patients at study entry before treatment with Alirocumab or Evolocumab
Age at entry (years) Mean ± SD, [25th, 50th, 75th percentiles] 64.1 ± 9.6, [58, 65, 72]
BMI (kg/m2) Mean ± SD, [25th, 50th, 75th percentiles] 29.3 ± 5.1, [25.3, 29.0, 32.2]
Race 62 White (86%), 8 Black (11%), 1 Asian (1%), 1 Indian (1%)
Gender 45 F (63%), 27 M (38%)
Diabetes 12 Yes (17%), 60 No (83%)
Smoke 5 Yes (7%), 67 No (93%)
BP lowering drug 45 Yes (63%), 27 No (38%)
HeFH 47 Yes (65%), 25 No (35%); 25 had HeFH & no CVD (35%)
CVD 47 Yes (65%), 25 No (35%); 25 had CVD & no HeFH (35%)
Both HeFH & CVD 22 (31%)
Statin intolerant 42 Yes (58%), 30 No (42%)
Medication use at entry Statin only, N = 16
Taking Statin (n = 30) Statin + ezetimibe, N = 5
Statin + colesevelam, N = 2
Statin + ezetimibe + colesevelam, N = 7
Not taking statin (n = 42) Ezetimibe only, N = 4
Colesevelam only, N = 2
Ezetimibe + colesevelam, N = 5
Nothing, N = 31
Follow up weeks on ALI or EVO Mean ± SD, [25th, 50th, 75th percentiles] 26 ± 5, [24, 28]
Table 2 Changes in LDLC and CVD risk from study entry to last follow up in 72 patients taking Alirocumab or Evolocumab
Alirocumab 75 mg
(n = 25) Follow up
length median 24 weeks
Alirocumab 150 mg
(n = 15) Follow up
length median 26 weeks
Evolocumab 140 mg
(n = 32) Follow up
length median 24 weeks
Variable measured percentile percentile percentile
25th 50th 75th 25th 50th 75th 25th 50th 75th
LDLC Entry (mg/dl) 100 117 143 133 175 214 143 165 211
Follow up (mg/dl) 47 62 84 49 57 86 46 69 109
Absolute change (mg/
dl)
−35 −67 −85 −89 −104 −141 −65 −89 −131
P (paired Wilcoxon) p <.0001 p <.0001 p <.0001
Percent change (%) −27 −54 −63 −56 −63 −72 −40 −63 −71
P (Wilcoxon) p <.0001 p <.0001 p <.0001
CVD risk for next 10 years With AHA
calculator
Entry (%) 3.9 6.2 18.0 5.4 9.3 20.4 4.3 11.5 18.6
Follow up (%) 3.3 6.2 10.1 2.3 7.0 15.1 2.9 6.7 20.2
Absolute change −0.2 −1.6 −5.4 −0.7 −3.3 −6.0 −0.6 −2.4 −5.7
P (paired Wilcoxon) p = .0001 p = .0043 p = <.0001
Percent change −1.9 −22.2 −40.7 −22.2 −31.3 −39.0 −9.1 −28.7 −52.3
P (Wilcoxon) p = .0002 p = .0015 p <.0001
CVD risk for next 10 years With NIH
calculator
Entry (%) 6.8 11.2 19.8 10.6 17.2 25.7 9.6 17.4 26.4
Follow up (%) 4.3 7.4 11.7 5.1 6.5 12.3 5.3 8.0 12.0
Absolute change −1.4 −4.2 −10.5 −4.4 −9.1 −16.2 −3.0 −7.1 −14.7
P (paired Wilcoxon) p <.0001 p = .0001 P <.0001
Percent change −21.4 −43.7 −53.5 −41.6 −49.8 −61.4 −27.9 −55.5 −66.2
P (Wilcoxon) p <.0001 p = .0001 p <.0001
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LDLC <70 mg/dl, Table 3. Of the 25 patients with CVD
only, 22 (88%) achieved LDLC <70 mg/dl. Of the 22 pa-
tients with both HeFH and CVD, 14 (64%) achieved
LDLC <70 mg/dl, Table 3.
As displayed in Table 3, of the 25 patients on ALI
75 mg, 19 (76%) achieved LDLC <70 mg/dl. Of the 15
patients on ALI 150 mg, 11 (73%) achieved LDLC
<70 mg/dl. Of 32 patients on EVO 140 mg, 18 (56%)
achieved LDLC <70 mg/dL. In the total cohort of 72 pa-
tients, 48 (67%) achieved LDLC <70 mg/dl, Table 3.
As shown in Table 4, reductions in LDLC were accom-
panied by median reduction in total cholesterol of 32%
(ALI 75 mg), 48% (ALI 150 mg), and 39% (EVO 140 mg),
p < .0001 for all. On ALI 75 mg, ALI 150 mg, and EVO
140 mg, there were also significant median reductions in
triglycerides (TG) of 21%, 32%, and 23% (p = .01, p = .002,
p = .009), respectively (Table 4). Median HDLC increased
5% on ALI 75 mg, 11% on ALI 150 mg and 8% on EVO
140 mg (p = .092, p = .010, p = .003, Table 4).
By stepwise regression, among age, race, BMI, gender,
statin intolerance (+/−), HeFH (+/−), CVD (+/−), PCSK9
treatment type, and follow-up duration, the only signifi-
cant explanatory variable for absolute change or percent
change in LDLC was PCSK9 treatment type. Using a
general linear model, adjusting for age, race, BMI, gen-
der, statin intolerance (+/−), HeFH (+/−), CVD (+/−)
and follow-up duration, absolute and percent LDLC re-
duction were greater with ALI 150 mg than with ALI
Table 3 Number (%) of patients who had at least one measure of LDLC <70 mg/dl on Alirocumab or Evolocumab for 24 weeks
HeFH only (n = 25) Entry
LDLC 25th, 50th, 75th%tile:
[149, 177, 220 mg/dl]
CVD only (n = 25)
[104, 131, 148 mg/dl]
HeFH & CVD (n = 22)
[122, 169, 214 mg/dl]
Total cohort (n = 72)
[123, 149, 193 mg/dl]
Alirocumab 75 mg/2 weeks (n = 25) 2/5 (40%) 12/14 (86%) 5/6 (83%) 19/25 (76%)
Alirocumab 150 mg/2 weeks (n = 15) 2/4 (50%) 3/3 (100%) 6/8 (75%) 11/15 (73%)
Evolocumab 140 mg/2 weeks (n = 32) 8/16 (50%) 7/8 (88%) 3/8 (38%) 18/32 (56%)
All 3 treatment groups (n = 72) 12/25 (48%) 22/25 (88%) 14/22 (64%) 48/72 (67%)
Table 4 Change in total cholesterol, triglyceride, and HDL cholesterol in 72 patients treated with Alirocumab or Evolocumab
Alirocumab 75 mg (n = 25)
Follow up length median
24 weeks
Alirocumab 150 mg (n = 15)
Follow up length median
26 weeks
Evolocumab 140 mg (n = 32)
Follow up length median
24 weeks
Variable measured percentile percentile percentile
25th 50th 75th 25th 50th 75th 25th 50th 75th
Total cholesterol Entry (mg/dl) 172 192 231 227 259 294 222 252 299
Follow up (mg/dl) 118 155 177 114 145 181 117 157 203
Absolute change (mg/dl) −25 −76 −94 −83 −105 −168 −65 −86 −139
P (paired Wilcoxon) p <.0001 p <.0001 p <.0001
Percent change (%) −14 −32 −45 −34 −48 −53 −26 −39 −52
P (Wilcoxon) p <.0001 p <.0001 p <.0001
Triglyceride Entry (mg/dl) 96 135 173 124 160 317 101 145 167
Follow up (mg/dl) 80 106 154 76 105 161 80 106 142
Absolute change (mg/dl) +3 −29 −57 −10 −51 −102 +4 −25 −52
P (paired Wilcoxon) p = .0051 p = .0015 p = .0069
Percent change (%) +3 −21 −33 −12 −32 −41 +4 −23 −35
P (Wilcoxon) p = .0097 p = .0015 p = .0092
HDL cholesterol Entry (mg/dl) 41 53 61 40 51 57 45 56 68
Follow up (mg/dl) 40 51 65 44 52 65 47 58 75
Absolute change (mg/dl) −1 +2 +5 +1 +7 +10 0 +4 +14
P (paired Wilcoxon) p = .070 p = .0075 p = .0028
Percent change (%) −2 +5 +11 +3 +11 +17 0 +8 +21
P (Wilcoxon) p = .092 p = .010 p = .0029
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75 mg (p = .004, p = .011), and greater with EVO 140 mg
than with ALI 75 mg (p = .014, p = .044), Table 5. ALI
150 mg and EVO 140 mg did not differ in regards to
LDLC reduction (p >0.05). In a second general linear
model, covariance adjusted absolute and % reduction in
LDLC on therapy was greater in the 30 statin-tolerant
patients who continued statins plus ALI or EVO for
24 weeks, versus the 42 patients with statin intolerance,
p = .0008, p = .013, Table 5.
Reductions in LDLC were accompanied by significant
absolute and percent reductions in estimated 10-year
CVD risk as determined by both the ACC/AHA and the
NIH calculators (Table 2). On ALI 75 mg, ALI 150 mg,
and EVO 140 mg, by the NIH calculator, at last follow-
Fig. 1 Median and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24 weeks follow-up on Alirocumab 75 mg every two weeks
Fig. 2 Median and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24 weeks follow-up on Alirocumab 150 mg every two weeks
Shah et al. Lipids in Health and Disease  (2017) 16:19 Page 6 of 12
up, 10-year CVD risk was reduced by median of 44, 50
and 56%, p ≤.0001 for all. By the AHA calculator, at last
follow-up, 10-year CVD risk was reduced by median of
22, 31 and 29%, p <.002 for all (Table 2).
Table 6 displays adverse events (AE) in the 72 patients
on the 3 treatment regimens. The three most common
adverse events were a flu-like myositis (10%), respiratory
tract symptoms/infection (8%), and injection site reac-
tion (6%), Table 6. As displayed in Table 6, there were
no significant differences among the 3 groups for AEs
(p >0.05).
As displayed in Table 7, the statin tolerant group, taking
a statin plus ALI or EVO, had fewer AEs than the statin
intolerant group, taking ALI or EVO only, 0 = .039.
One patient had coronary bypass revision due to scar
tissue growth within one month of starting therapy and
another patient had three stents placed within two
months of starting therapy. In neither of the cardiovas-
cular event patients was the PCSK9 inhibitor therapy
stopped and we did not attribute these two events to the
PCSK9 inhibitor therapy.
Discussion
After taking into account the rising CVD costs in the
United States, projected by the AHA to be approxi-
mately $1 trillion by 2030, we have postulated that the
cost to society with an estimated 50% CVD risk reduc-
tion with PCSK9 inhibitor therapy [6, 10, 11] would be
in the middle of the range of societal costs for CVD [6].
Subsequently, in 103 hypercholesterolemic patients [7]
(61 with previous CVD events, first CVD event at me-
dian age 55, median LDLC 139 mg/dL despite maximal
tolerated cholesterol-lowering therapy), we estimated
direct and indirect costs of CVD, cost of estimated next
Fig. 3 Median and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24 weeks follow-up on Evolocumab 140 mg every two weeks
Table 5 Comparisons of LDLC change among PCSK9 inhibitor treatment groups and between statin tolerant and intolerant groups
Alirocumab 75 mg (n = 25) Alirocumab 150 mg (n = 15) Evolucumab 140 mg (n = 32)
LS means ± SE of change in LDLC (mg/dl) −59 ± 10 −110 ± 14 −95 ± 9
Group differences ALI 75 vs ALI 150, p = .004
ALI 75 vs EVO 140, p = .014
LS means ± SE of % change in LDLC (%) −42 ± 5% −63 ± 7% −56 ± 4%
Group differences ALI 75 vs ALI 150, p = .011
ALI 75 vs EVO 140, p = .044
LS means ± SE of change in LDLC (mg/dl) −109 ± 7 −78 ± 5
Group differences p = .0008
LS means ± SE of % change in LDLC (%) −63 ± 5% −48 ± 4%
Group differences p = .013
LS means for 3 treatment groups, adjusted for treatment duration, age, BMI, race, gender, statin intolerance (yes-no), HeFH (yes-no), and CVD (yes-no)
LS means for statin tolerant vs intolerant groups, adjusted for PCSK9 groups, treatment duration, age, BMI, race, gender, HeFH (yes-no), CVD (yes-no) and LDLC
at entry
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10-year CVD events, and PCSK9 inhibitor costs to as-
sess whether PCSK9 inhibitors would provide an incre-
mental cost-effectiveness ratio [21] within a society
willingness to pay threshold [22]. We concluded [7] that
the net cost of PCSK9 inhibitor therapy, assuming a 50%
reduction of CVD events on PCSK9 inhibitor therapy,
was $7,000 per patient per year in the past, and the net
cost of therapy over the next 10 year period was esti-
mated to be $12,459 per patient per year, well below the
$50,000 per quality adjusted life year [22] gained which
has been used to judge value of a pharmacologic
therapy.
Despite maximal tolerated cholesterol lowering ther-
apy, many patients fail to achieve optimal LDLC lower-
ing [23–25], with only 28% of patients in NHANES
achieving LDLC <70 mg/dl on treatment [17]. Failure to
reach optimal LDLC lowering is related to statin intoler-
ance [26, 27], expense, lack of insurance coverage, or
variations in statin availability across states in insurance,
race, and ethnicity [23]. In the current study, 42 of 72
Table 6 Adverse events in 72 patients on Alirocumab 75 or 150 mg, or Evolocumab 140 mg, by treatment regimens
All 3 treatment groups (n = 72)
F45, M27 Follow up length
median 25 weeks
Alirocumab 75 mg (n = 25)
F12, M13 Follow up length
median 24 weeks
Alirocumab 150 mg (n = 15)
F10, M5 Follow up length
median 26 weeks
Evolocumab 140 mg (n = 32)
F23, M9 Follow up length
median 24 weeks




6 (8%) 1 (4%) 1 (7%) 4 (13%)
Inject site
reaction
4 (6%) 1 (4%) 1 (7%) 2 (6%)




2 (3%) 1 (7%) 1 (3%)
Urticaria/
itchiness
2 (3%) 1 (4%) 1 (3%)
G.I. symptom 2 (3%) 1 (7%) 1 (3%)
Weight gain 1 (1%) 1 (3%)
Hair loss 1 (1%) 1 (3%)
Any adverse
events
22 (31%) 5 (20%) 7 (47%) 10 (31%)
No adverse
events
50 (69%) 20 (80%) 8 (53%) 22 (69%)
Comparing adverse events (any vs none), no difference among 3 treatment groups (Fisher’s p > .05)
Table 7 Adverse events in 72 patients on Alirocumab or Evolocumab, by entry statin intolerance group
All (n = 72) F45, M27 Follow up
length median 25 weeks
Statin tolerant, taking statin (n = 30) F15, M15
Follow up length median 24 weeks
Statin intolerant (n = 42) F30, M12 Follow
up length median 23 weeks
Flu-like myositis 8 (10%) 1 (3%) 7 (17%)
Respiratory tract
infection/symptoms
6 (8%) 2 (7%) 4 (9%)
Inject site reaction 4 (6%) 2 (7%) 2 (5%)
Fatigue 1 (1%) 1 (2%)
Headache/mental
acuity/mood
2 (3%) 2 (5%)
Urticaria/itchiness 2 (3%) 2 (5%)
G.I. symptom 2 (3%) 2 (5%)
Weight gain 1 (1%) 1 (2%)
Hair loss 1 (1%) 1 (2%)
Any adverse events 22 (31%) 5 (17%) 17 (40%)
No adverse events 50 (69%) 25 (83%) 25 (60%)
Comparing adverse events (any vs none), there were fewer adverse events in the statin tolerant group, taking statin + ALI or EVO than in the statin intolerant
group taking ALI or EVO only (Fisher’s p = .039)
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patients (58%) were statin intolerant, a problem which af-
fects at least 10-29% of patients taking statins [14, 15, 28].
Moreover 60% of patients who discontinue statins report
statin intolerance as the reason [29]. However, congruent
with our open label, post commercialization study, as
demonstrated by the controlled clinical trial, GAUSS-3, in
patients with statin intolerance, EVO was well-tolerated
and effective [8]. PCSK9 inhibitors now offer the promise
of optimizing LDLC in most patients with HeFH, CVD,
and concurrent statin intolerance [9–12, 30–32].
ALI and EVO have been found to be very efficacious
and safe during phase II and III randomized controlled
trials with minimal adverse events compared to placebo
[8, 9, 11]. In the phase II MENDEL study, without a con-
current lipid-lowering regimen, EVO 140 mg showed a
51% reduction in LDLC at 12 weeks [33]. In
SAR236553/REGN727 phase II trials with ALI 150 mg
added on a stable atorvastatin dose, there was 72%
LDLC reduction at 12 weeks [34]. During phase III trials
with patients on maximal tolerated cholesterol lowering
therapy along with ALI 150 mg and ALI 75 mg every
two weeks, there was a 61 and 46% reduction, respect-
ively, from baseline in LDLC at median 24 weeks [3, 9].
In OSLER-1 and 2, patients on EVO 140 mg every two
weeks or 420 mg once/month had LDLC reduction by
61% at median 12 weeks on top of antecedent choles-
terol lowering therapy [11].
Based on FDA indications and third party insurance
drug coverage, our current study was done in HeFH and
CVD patients with suboptimal cholesterol lowering des-
pite maximal tolerated cholesterol lowering therapy.
This qualified all our cohort, with minimal exclusion cri-
teria, for initiation of PCSK9 inhibitor therapy, a cohort
much more diverse than those in the placebo-controlled
randomized clinical trials [9, 11]. Rallidis et al. have re-
cently demonstrated that in patients who presented with
myocardial infarction, 20% had definite/probable HeFH
and 51% had possible HeFH [35]. Over a 9-year follow-
up period, 39% of 255 patients had a major adverse cor-
onary event despite 84.3% being on statins, with only
2.3% achieving LDLC <70 mg/dl [35]. Definite/probable
HeFH was independently associated with major adverse
coronary events [35]. Our current study cohort included
25 patients with HeFH only, 25 with CVD only, and 22
with both. Moreover, in our current study, 48/72 (67%)
patients obtained optimal LDLC reduction to <70 mg/dl
while taking ALI or EVO. Of the 25 patients with HeFH
only, 12 (48%) had ≥ 1 LDLC < 70 mg/dl on therapy, as
did 22 of 25 (88%) patients with CVD only, and 14 of 22
(64%) with both HeFH and CVD. Our findings support
the central importance of PCSK9 inhibitor therapy in
high-risk patients with HeFH and/or CVD who other-
wise do not achieve LDLC <70 mg/dl with maximal tol-
erated LDLC lowering regimens.
In our current study, median absolute reductions in
LDLC on ALI 75 mg, ALI 150 mg, and EVO 140 mg were
respectively 67, 104, and 89 mg/dl, which, if maintained,
should lead to sharp reductions in CVD events. In our
current study, median LDLC reduction from baseline was
54% and 63% on ALI 75 and 150 mg, and 63% on EVO
140 mg respectively at 24 weeks. Collins et al. reported
that reduction of LDLC by 77 mg/dl for 5 years in 10,000
patients would prevent major vascular events in 1,000
(10%), an absolute benefit in those who had pre-existing
CVD, and in 500 patients (5% absolute benefit) in primary
prevention [36]. In the 30 statin-tolerant patients in our
current study, subsequently receiving both statins and ALI
or EVO, absolute and percent LDLC reduction was
greater than in the 42 patients with statin intolerance at
entry who subsequently received only ALI or EVO. LDLC
reduction in our real world setting for ALI 150 mg and
EVO 140 mg was within 1-2% of that reported in the pla-
cebo controlled trials while in the ALI 75 mg group it was
about 9% higher than the previous trials [9, 11].
From past vascular studies on statins, regression of
plaque can be induced when LDLC is held ~70 mg/dl or
below [37]. Patients receiving atorvastatin 80 mg have been
shown to have regression of carotid-artery intima-media
within 12 months with an average achieved LDLC of
76 mg/dl [38]. The NIH post-CABG study showed that pa-
tients who were post CABG and selected for a lower target
LDLC group (90 mg/dl vs 135 mg/dl) had no angiographic
progression of coronary plaques. This suggested that lower
target LDLC leads to a significant reduction in coronary
events and mortality, inferring that further reduction of
coronary plaque burden could lead to further reduced cor-
onary event rates and mortality [39]. When patients were
given rosuvastatin 40 mg in the ASTEROID trial, mean
LDLC was reduced from 130 mg/dl to 60 mg/dl (53%) with
a total atheroma volume reduction median of 6.8% as well
as a significant reduction in all intravenous ultrasound
measurements of atheroma burden [40]. Consequently, in
the recent GLAGOV study [41], compared with statin-
placebo, the EVO-statin group achieved lower mean LDLC
(93.0 vs 36.6 mg/dL, p <.001). The primary efficacy param-
eter, percent atheroma volume (PAV), increased 0.05% with
placebo and decreased 0.95% with EVO, p <.001).
EVO induced plaque regression in more patients than
placebo (64.3% vs 47.3%, p <.001 for PAV, and 61.5%
vs 48.9%, p <.001 for total atheroma volume (TAV)).
The GLAGOV study also demonstrated a positive lin-
ear change in percent PAV as LDLC increased from
20 mg/dl to 110 mg/dl.
Mendelian randomization studies suggest that a life-
time reduction of LDLC ~40 mg/dl would reduce risk of
ASCVD by 50% [42]. In our current study, the median
LDLC reduction ranged from 67 to 104 mg/dl, and 48
(67%) of 72 patients achieved at least one LDLC on
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therapy <70 mg/dl. Moreover, according to the AHA
and NIH 10-year CVD risk calculations, on ALI 75 mg
there was CVD risk reduction of 22 and 44%, on ALI
150 mg, 31 and 50%, and on EVO 140 mg, 29 and 56%.
The ACC/AHA calculator was not, however, designed
for use in patients with pre-existing CVD events, al-
though the NIH calculator has no such restriction [43].
In at least 50% of our patients on PCSK9 therapy with
LDLC < 70 mg/dl, from the past experience with vascu-
lar studies on statins [37, 38, 40] and recent GLAGOV
study [38], we speculate that there should be significant
regression of vascular plaque. Although not powered for
CVD outcomes, the preliminary randomized controlled
trials outcomes’ data for ALI and EVO showed 50%
CVD event reduction [9–11]. Further hard CVD end-
point as well as vascular regression studies [41] are
needed to assess for cardiovascular impact of the power-
ful LDLC reduction from PCSK9 therapy.
Assessment of potential adverse events is an important
consideration when analyzing PCSK9 inhibitor use. In the
current study, both ALI and EVO were generally well-
tolerated; the most significant frequent adverse event was
flu-like myositis-myalgia in 10% of patients. There were
however, no among-group differences between all three
treatment groups for adverse events (p >0.05). This is
comparable to the pattern of side effects for ALI and EVO
in randomized placebo-controlled trials [44, 45]. In a
meta-analysis of 25 randomized controlled trials with
PCSK9 inhibitors, there was no significant differences in
major adverse event rates between the active drug and
control treatment [46].
In the current study, of the 42 statin-intolerant patients,
defined primarily as experiencing myalgias or myopathy
on statins, 17% had mild to moderate flu-like myalgias.
When comparing the statin-intolerant cohort on ALI or
EVO versus those taking a statin plus ALI or EVO, there
were fewer adverse events in the statin tolerant group than
the statin intolerant group (p = .04). Our results parallel
those of the randomized, placebo-controlled GAUSS-3
study, where EVO was well-tolerated and effective in pa-
tients with statin intolerance [8]. Our conjecture is that
the long-term adverse health consequences attributed to
PCSK9 inhibitors may be minimal, particularly in statin
tolerant patients.
In our real world, open label, post-commercialization
evaluation of ALI and EVO, with 58% of patients being sta-
tin intolerant, and all having HeFH and/or CVD, our LDLC
reduction was within 1-3% of the placebo-controlled trials
for ALI 150 mg and EVO 140 mg groups, but the ALI
75 mg group had 9% higher LDLC lowering than earlier tri-
als [9, 11]. A second strength of our study was the finding
that the adverse event profile on ALI or EVO was slightly
lower in the statin tolerant patients taking both statins and
ALI or EVO versus the statin intolerant patients taking only
ALI or EVO. Since 58% of the cohort was intolerant to any
statin at any dose regimen at entry, this emphasizes both
the high frequency of statin intolerance in patients with
high LDLC who fail to reach LDLC goals, and the efficacy
of ALI and EVO inhibitors in stain intolerant patients. A
third strength lies in the characterization of those patients
who achieved LDLC <70 mg/dl by each treatment group,
and in the presence or absence of HeFH and/or CVD.
A limitation of this study is the relatively small group
of patients. A second limitation is a probable bias to-
wards higher risk patients with HeFH, CVD, and statin
intolerance, unable to reach LDLC lowering goals on
conventional LDLC-lowering therapy, by virtue of refer-
ral to a regional cholesterol treatment center.
Conclusion
In hypercholesterolemic patients with HeFH, and/or CVD
with suboptimal LDLC lowering on maximal tolerated
cholesterol lowering therapy, LDLC was reduced by 63%
on EVO 140 mg and ALI 150 mg and 54% on ALI 75 mg
beyond the best antecedent cholesterol lowering program.
Reported adverse events were minimal and tolerable. ALI
and EVO represent paradigm shifts in LDLC lowering,
and, speculatively, in reduction of CVD, with long-term
safety and cardiovascular outcomes yet to be determined.
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